Cargando…

Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI

INTRODUCTION: The optimal timing and modality of therapeutic intervention during early phases of HIV infection is still debated; in our prospective observational study we evaluated immunological and virological outcome in HIV+ patients treated during acute or recent HIV infection. MATERIALS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maria Bottani, Giulia, Letizia Oreni, Maria, Orofino, Giancarlo, Tau, Pamela, Di Nardo Stuppino, Silvia, Colella, Elisa, Carosella, Sinibaldo, Guastavigna, Marta, Ghisetti, Valeria, Micheli, Valeria, Galli, Massimo, Rusconi, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P246
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225434/ https://www.ncbi.nlm.nih.gov/pubmed/25397522 http://dx.doi.org/10.7448/IAS.17.4.19778

Ejemplares similares

Impact de l’infection par le SARS-CoV-2 chez les patients suivis pour cancer du poumon
por: Chatti, A., et al.
Publicado: (2022)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Preliminary validation of bumby RAPE and MOLEST scales: Exploratory factorial analysis
por: Baúto, Ricardo Ventura, et al.
Publicado: (2021)

L’insuffisance surrénalienne aiguë : une complication à ne pas méconnaître de la Covid-19
por: Bougossa, R., et al.
Publicado: (2021)

Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time
por: Livelli, Alessandro, et al.
Publicado: (2015)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects
por: Giacomelli, Andrea, et al.
Publicado: (2019)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Who gets single tablet regimens (STR), and why?
por: Tarrier, Laura, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice
por: Ferrer, Elena, et al.
Publicado: (2014)

Patients’ willingness to take separate component antiretroviral therapy regimens for HIV in the Netherlands
por: Engelhard, Esther, et al.
Publicado: (2014)

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
por: Kiselinova, Maja, et al.
Publicado: (2014)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL
por: Dentone, Chiara, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
por: Sweet, Donna, et al.
Publicado: (2014)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
por: Maggiolo, Franco, et al.
Publicado: (2014)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Louseborne Relapsing Fever among East African Refugees, Italy, 2015
por: Lucchini, Anna, et al.
Publicado: (2016)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study
por: Trottier, Benoit, et al.
Publicado: (2014)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Predictors of lack of serological response to syphilis treatment in HIV-infected subjects
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m30jhu3akik68gfolqbho36dq5